- Home
- TRST vs CRGX Comparison
TRST vs CRGX Comparison
Compare TRST & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRST
- CRGX
- Stock Information
- Founded
- TRST 1902
- CRGX 2021
- Country
- TRST United States
- CRGX United States
- Employees
- TRST N/A
- CRGX N/A
- Industry
- TRST Major Banks
- CRGX
- Sector
- TRST Finance
- CRGX
- Exchange
- TRST Nasdaq
- CRGX Nasdaq
- Market Cap
- TRST 540.7M
- CRGX 190.0M
- IPO Year
- TRST N/A
- CRGX 2023
- Fundamental
- Price
- TRST $35.10
- CRGX $4.40
- Analyst Decision
- TRST
- CRGX Hold
- Analyst Count
- TRST 0
- CRGX 7
- Target Price
- TRST N/A
- CRGX $4.67
- AVG Volume (30 Days)
- TRST 107.4K
- CRGX 527.8K
- Earning Date
- TRST 07-21-2025
- CRGX 08-11-2025
- Dividend Yield
- TRST 4.11%
- CRGX N/A
- EPS Growth
- TRST N/A
- CRGX N/A
- EPS
- TRST 2.68
- CRGX N/A
- Revenue
- TRST $173,999,000.00
- CRGX N/A
- Revenue This Year
- TRST $13.13
- CRGX $57.81
- Revenue Next Year
- TRST N/A
- CRGX N/A
- P/E Ratio
- TRST $12.87
- CRGX N/A
- Revenue Growth
- TRST N/A
- CRGX N/A
- 52 Week Low
- TRST $27.18
- CRGX $3.00
- 52 Week High
- TRST $38.89
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- TRST 77.05
- CRGX 55.41
- Support Level
- TRST $33.29
- CRGX $4.09
- Resistance Level
- TRST $33.73
- CRGX $4.31
- Average True Range (ATR)
- TRST 0.74
- CRGX 0.19
- MACD
- TRST 0.36
- CRGX -0.01
- Stochastic Oscillator
- TRST 99.35
- CRGX 61.61
About TRST TrustCo Bank Corp NY
Trustco Bank Corp N Y is a savings and loan holding company. The core part of a business consists of accepting deposits and making loans and investments. It offers a range of both personal and business banking services. The company's product includes savings accounts; retirement accounts; money market account; mortgages; building loans; auto loans and others. The company based on only one business segment, that of community banking. TrustCo lends in the geographic territory of its branch locations in New York, Florida, Massachusetts, New Jersey, and Vermont.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.